



**Figure S1.** 4-12% SDS-PAGE gel showing T3SP preparations used to elicit antigen recall responses.




**Figure S2.** Gating strategy used for analysis of Ki67 expression by *ex-vivo* re-stimulated rectal lymph node cells.


a. Morphology:





b. Vital stain:





c. Fluorescence minus one (FMO) controls:





d. CD4<sup>+</sup> cell gating:





e. CD8<sup>+</sup> cell gating:



f. TcR1-N24( $\delta$ )<sup>+</sup> cell gating:



g. NKp46<sup>+</sup> cell gating:



**Table S1.** External primers used for cloning of gene fragments for standard curve plasmid generation.

<b>Gene</b>	<b>Direction</b>	<b>Sequence</b>
FoxP3	F	GGAGTGGGTTTCCAGGGAGCCA
	R	TGCCTGGCAGTGCTTGAGGAA
T-bet	F	GGGCTTCCAACAATGCGACCCA
	R	AAGTTCTCCCGGAATCCTTTGGC
IL17	F	CCGGAGCACAAACTCCAGAAGGC
	R	TGATGGTCCACCTTCCCTTCAGC
IL22	F	CGAAGCGCTGCTACGTGCTGAA
	R	TCTGGATGTGCTGGTTGTCAGACTC
RORC	F	CCGGGCCTACAACGCTGACA
	R	AAAGGCCAGCTCCAGATTGCAC
GATA3	F	ACCATACGTCCCCGAGTACAGC
	R	TACCTGCCCTTCTTGCTGCCGA

**Table S2.** Internal primers used for RT-qPCR analysis of gene expression.

Gene	Direction	Sequence	Reference
FoxP3	F	GACAGCACCCCTTTCGACTGT	
	R	CCACTTGCAGACGCCATTTG	
GATA3	F	TGTGTGAACTGTGGGGCGACAT	
	R	TACACAGGTAATGCCCGGTTCCGT	
IFN $\gamma$	F	CTTGAATGGCAGCTCTGAGAAA	(1)
	R	TGCAGATCATCCACCGGAAT	
T-bet	F	GGGCTTCCAACAATGCGACCCA	
	R	AAGTTCTCCCGGAATCCTTTGGC	
IL17	F	CCGGAGCACAAACTCCAGAAGGC	
	R	TGATGGTCCACCTTCCCTTCAGC	
RORC	F	GAGTGCCTTGCGCTTTTCA	(1)
	R	AAAGGCCAGCTCCAGATTGCAC	
TNF $\alpha$	F	TCTACCAGGGAGGAGTCTTCCA	(1)
	R	TGCACCCTCACAGGGCGATGAT	
IL10	F	GCGGCGCTGTCATCGCTTTC	
	R	GATGAAGATGTCAAACCTCACTCATGG	
IL4	F	GCCACA CGTGCT TGAACAAA	(2)
	R	TGCTTGCCAAGC TGTTGAGA	
IL22	F	GTGCTGTTCCCCCAATCTGA	
	R	AGCTTTTTGCTGAGCCTGGA	
IL13	F	GGATGACACTGCAGTTGGAGA	
	R	TCTGCTACAGCCCTCAAGGA	
TGF $\beta$ <sub>1</sub>	F	CGCTGCCCGAGGCCATACTG	
	R	GCTCAGGCTCCGTTTCGGCA	

**Table S3.** qPCR standard curve dynamic range.

Gene	Gene copies/well		Regression $r^2$ range (all plates)
	Top standard	Bottom standard	
ATP5B	$10^6$	$10^3$	0.990-0.995
GAPDH	$10^6$	$10^3$	0.998-0.999
FoxP3	$10^7$	$10^2$	0.991-0.995
GATA3	$10^7$	$10^3$	0.996-0.996
IFN $\gamma$	$10^7$	$10^2$	0.997-0.999
T-bet	$10^7$	$10^3$	0.995-0.998
IL17	$10^7$	$10^4$	0.996-0.999
RORC	$10^7$	$10^2$	0.993-0.999
TNF $\alpha$	$10^7$	$10^2$	0.994-0.999
IL10	$10^6$	$10^2$	0.993-0.997
IL4	$10^7$	$10^2$	0.994-0.998
IL22	$10^8$	$10^3$	0.996-0.997
IL13	$10^7$	$10^3$	0.983-0.993
TGF $\beta_1$	$10^7$	$10^1$	0.994-0.996



**Table S4.** Test results for the fixed effects of the linear mixed models used to analyse changes in gene expression at the terminal rectum.

Gene	Fixed Effect	Num DF	Den DF	F Value	Pr > F
FoxP3	Log10(Expression pre-challenge)	1	6	5.31	0.0607
FoxP3	Experimental group	2	6	1.63	0.2729
FoxP3	Days post challenge	3	21	1.92	0.1575
FoxP3	Days*group interaction	6	21	2.35	0.0679
GATA3	Log10(Expression pre-challenge)	1	6	29.71	0.0016
GATA3	Experimental group	2	6	0.75	0.5105
GATA3	Days post challenge	3	21	4.64	0.0122
GATA3	Days*group interaction	6	21	1.09	0.402
IFN $\gamma$	Log10(Expression pre-challenge)	1	6	9.87	0.02
IFN $\gamma$	Experimental group	2	6	3.25	0.1107
IFN $\gamma$	Days post challenge	3	21	1.49	0.245
IFN $\gamma$	Days*group interaction	6	21	4.11	0.007
IL10	Log10(Expression pre-challenge)	1	6	15.96	0.0072
IL10	Experimental group	2	6	3.76	0.0875
IL10	Days post challenge	3	21	3.02	0.0528
IL10	Days*group interaction	6	21	2.98	0.0288
IL17	Log10(Expression pre-challenge)	1	6	31.23	0.0014
IL17	Experimental group	2	6	3.53	0.097
IL17	Days post challenge	3	21	2.45	0.0917
IL17	Days*group interaction	6	21	0.26	0.9506
IL22	Log10(Expression pre-challenge)	1	6	21.39	0.0036
IL22	Experimental group	2	6	4.81	0.0566
IL22	Days post challenge	3	21	2.97	0.0551
IL22	Days*group interaction	6	21	0.69	0.6567
RORC	Log10(Expression pre-challenge)	1	6	101.22	<.0001
RORC	Experimental group	2	6	0.56	0.5959
RORC	Days post challenge	3	21	2.27	0.1105
RORC	Days*group interaction	6	21	0.29	0.9354
Tbet	Log10(Expression pre-challenge)	1	6	36.15	0.001
Tbet	Experimental group	2	6	10.66	0.0106
Tbet	Days post challenge	3	21	8.46	0.0007
Tbet	Days*group interaction	6	21	11.77	<.0001
TGF $\beta$ 1	Log10(Expression pre-challenge)	1	6	5.54	0.0567
TGF $\beta$ 1	Experimental group	2	6	25.44	0.0012
TGF $\beta$ 1	Days post challenge	3	21	5.36	0.0067
TGF $\beta$ 1	Days*group interaction	6	21	15.27	<.0001
TNF $\alpha$	Log10(Expression pre-challenge)	1	6	13.9	0.0098
TNF $\alpha$	Experimental group	2	6	4.34	0.0683
TNF $\alpha$	Days post challenge	3	21	1.48	0.2496

TNF $\alpha$	Days*group interaction	6	21	0.32	0.9188
--------------	------------------------	---	----	------	--------

**Table S5.** Predicted means and 95% confidence intervals from the linear mixed models used to analyse changes in gene expression at the terminal rectum.

Gene	Group	Days post challenge	Estimated Fold Change	95% CIs		t Value	p
				Lower	Upper		
IFNg	Control	7	0.73	0.36	1.51	-0.89	0.3837
IFNg	PT2128	7	0.96	0.59	1.58	-0.15	0.8815
IFNg	PT32	7	2.79	1.72	4.52	4.41	0.0002
IFNg	Control	14	1.14	0.55	2.34	0.37	0.7146
IFNg	PT2128	14	0.81	0.49	1.32	-0.90	0.3802
IFNg	PT32	14	2.35	1.45	3.81	3.67	0.0014
IFNg	Control	21	1.08	0.53	2.23	0.23	0.8185
IFNg	PT2128	21	2.47	1.51	4.04	3.83	0.001
IFNg	PT32	21	1.62	1.00	2.63	2.09	0.0492
IFNg	Control	31	1.15	0.56	2.36	0.40	0.6906
IFNg	PT2128	31	1.16	0.71	1.90	0.63	0.5357
IFNg	PT32	31	0.86	0.53	1.40	-0.63	0.5328
Tbet	Control	7	0.38	0.21	0.69	-3.42	0.0026
Tbet	PT2128	7	1.69	1.11	2.59	2.60	0.0169
Tbet	PT32	7	2.93	1.93	4.44	5.37	<.0001
Tbet	Control	14	1.11	0.62	2.00	0.38	0.7079
Tbet	PT2128	14	0.50	0.33	0.76	-3.40	0.0027
Tbet	PT32	14	0.61	0.40	0.92	-2.49	0.0214
Tbet	Control	21	0.22	0.12	0.39	-5.39	<.0001
Tbet	PT2128	21	2.09	1.37	3.19	3.63	0.0016
Tbet	PT32	21	0.55	0.36	0.83	-3.03	0.0064
Tbet	Control	31	0.53	0.29	0.95	-2.26	0.0346
Tbet	PT2128	31	0.34	0.23	0.53	-5.25	<.0001
Tbet	PT32	31	0.58	0.38	0.88	-2.70	0.0133
TNFa	Control	7	0.97	0.58	1.64	-0.11	0.9146
TNFa	PT2128	7	0.99	0.68	1.43	-0.07	0.9442
TNFa	PT32	7	1.29	0.89	1.87	1.42	0.1706
TNFa	Control	14	1.28	0.76	2.16	0.99	0.3324
TNFa	PT2128	14	1.05	0.73	1.53	0.30	0.7696
TNFa	PT32	14	1.26	0.86	1.82	1.27	0.2182
TNFa	Control	21	0.75	0.44	1.26	-1.16	0.2577
TNFa	PT2128	21	0.97	0.67	1.41	-0.16	0.8772
TNFa	PT32	21	1.38	0.95	2.00	1.79	0.0887
TNFa	Control	31	0.74	0.44	1.24	-1.22	0.2342
TNFa	PT2128	31	0.81	0.55	1.17	-1.20	0.2419
TNFa	PT32	31	0.94	0.65	1.37	-0.33	0.7434
GATA3	Control	7	1.33	0.57	3.13	0.70	0.4897
GATA3	PT2128	7	1.11	0.60	2.06	0.35	0.7277

GATA3	PT32	7	0.76	0.45	1.29	-1.07	0.2989
GATA3	Control	14	0.94	0.40	2.19	-0.16	0.872
GATA3	PT2128	14	1.96	1.06	3.64	2.27	0.0337
GATA3	PT32	14	1.25	0.74	2.12	0.88	0.3894
GATA3	Control	21	1.34	0.57	3.13	0.70	0.4886
GATA3	PT2128	21	2.23	1.20	4.14	2.70	0.0134
GATA3	PT32	21	2.65	1.56	4.50	3.83	0.001
GATA3	Control	31	0.51	0.22	1.19	-1.66	0.1109
GATA3	PT2128	31	1.34	0.72	2.48	0.97	0.3414
GATA3	PT32	31	0.85	0.50	1.44	-0.66	0.5168
IL17	Control	7	0.73	0.42	1.28	-1.17	0.2558
IL17	PT2128	7	1.08	0.73	1.60	0.39	0.699
IL17	PT32	7	1.32	0.89	1.97	1.46	0.1596
IL17	Control	14	0.81	0.46	1.41	-0.80	0.4314
IL17	PT2128	14	0.80	0.54	1.18	-1.19	0.2466
IL17	PT32	14	0.88	0.59	1.31	-0.66	0.5146
IL17	Control	21	0.63	0.36	1.10	-1.72	0.0992
IL17	PT2128	21	0.85	0.57	1.26	-0.88	0.3862
IL17	PT32	21	0.87	0.59	1.30	-0.72	0.4823
IL17	Control	31	0.57	0.32	0.99	-2.11	0.0467
IL17	PT2128	31	0.55	0.37	0.81	-3.16	0.0047
IL17	PT32	31	0.70	0.47	1.04	-1.90	0.0713
IL22	Control	7	1.22	0.42	3.54	0.38	0.706
IL22	PT2128	7	0.43	0.20	0.89	-2.40	0.0257
IL22	PT32	7	0.65	0.31	1.34	-1.24	0.2271
IL22	Control	14	0.73	0.25	2.11	-0.62	0.541
IL22	PT2128	14	0.78	0.37	1.63	-0.71	0.4876
IL22	PT32	14	1.95	0.94	4.04	1.89	0.0722
IL22	Control	21	1.52	0.52	4.42	0.82	0.4238
IL22	PT2128	21	0.64	0.31	1.34	-1.25	0.2252
IL22	PT32	21	1.55	0.75	3.23	1.25	0.2245
IL22	Control	31	0.55	0.19	1.61	-1.15	0.2633
IL22	PT2128	31	0.36	0.17	0.76	-2.86	0.0094
IL22	PT32	31	0.44	0.21	0.92	-2.31	0.0314
FoxP3	Control	7	4.67	1.50	14.54	2.82	0.0102
FoxP3	PT2128	7	0.35	0.13	0.96	-2.16	0.0423
FoxP3	PT32	7	1.62	0.67	3.89	1.14	0.2675
FoxP3	Control	14	1.89	0.61	5.89	1.17	0.2564
FoxP3	PT2128	14	1.48	0.54	4.06	0.80	0.4307
FoxP3	PT32	14	2.14	0.89	5.16	1.81	0.0851
FoxP3	Control	21	0.98	0.32	3.06	-0.03	0.9736
FoxP3	PT2128	21	0.44	0.16	1.22	-1.67	0.1091
FoxP3	PT32	21	2.77	1.15	6.67	2.42	0.0249
FoxP3	Control	31	1.11	0.36	3.45	0.19	0.8511

FoxP3	PT2128	31	0.56	0.20	1.54	-1.20	0.2441
FoxP3	PT32	31	1.08	0.45	2.61	0.19	0.8519
IL10	Control	7	0.67	0.38	1.18	-1.48	0.1528
IL10	PT2128	7	0.58	0.40	0.84	-3.04	0.0062
IL10	PT32	7	1.08	0.73	1.60	0.40	0.693
IL10	Control	14	0.65	0.37	1.14	-1.60	0.1252
IL10	PT2128	14	0.81	0.56	1.16	-1.22	0.2352
IL10	PT32	14	0.99	0.67	1.47	-0.04	0.9695
IL10	Control	21	1.59	0.90	2.81	1.69	0.1051
IL10	PT2128	21	0.66	0.46	0.96	-2.34	0.0295
IL10	PT32	21	1.46	0.98	2.17	1.99	0.0593
IL10	Control	31	0.42	0.24	0.74	-3.17	0.0047
IL10	PT2128	31	1.02	0.71	1.48	0.12	0.9045
IL10	PT32	31	0.92	0.62	1.36	-0.45	0.6563
TGFb	Control	7	12.64	4.89	32.70	5.55	<.0001
TGFb	PT2128	7	0.05	0.02	0.11	-8.14	<.0001
TGFb	PT32	7	1.27	0.81	1.98	1.12	0.2759
TGFb	Control	14	5.46	2.11	14.13	3.72	0.0013
TGFb	PT2128	14	0.30	0.14	0.63	-3.32	0.0032
TGFb	PT32	14	2.38	1.53	3.71	4.07	0.0005
TGFb	Control	21	7.87	3.04	20.35	4.52	0.0002
TGFb	PT2128	21	0.09	0.04	0.20	-6.45	<.0001
TGFb	PT32	21	5.49	3.53	8.56	7.99	<.0001
TGFb	Control	31	2.70	1.04	6.97	2.17	0.0416
TGFb	PT2128	31	0.21	0.10	0.46	-4.23	0.0004
TGFb	PT32	31	2.48	1.59	3.86	4.25	0.0004
RORC	Control	7	1.03	0.57	1.85	0.10	0.9193
RORC	PT2128	7	0.85	0.56	1.30	-0.79	0.4387
RORC	PT32	7	0.79	0.52	1.20	-1.17	0.2541
RORC	Control	14	0.50	0.28	0.89	-2.48	0.0218
RORC	PT2128	14	0.56	0.37	0.85	-2.88	0.0089
RORC	PT32	14	0.57	0.38	0.87	-2.79	0.0111
RORC	Control	21	0.61	0.34	1.10	-1.74	0.0957
RORC	PT2128	21	0.57	0.38	0.87	-2.78	0.0112
RORC	PT32	21	0.77	0.51	1.17	-1.30	0.2076
RORC	Control	31	0.48	0.27	0.86	-2.61	0.0164
RORC	PT2128	31	0.61	0.40	0.92	-2.50	0.0206
RORC	PT32	31	0.60	0.39	0.91	-2.56	0.0183

**Table S6.** Stimulation Index Tukey comparisons for data in Figure 4A. Pairwise comparisons were made between the  $\Delta sepL$  and WT T3SP preparations at each lymph node (RLN/MLN/PsLN) and the same T3SP preparation between each lymph node.

<b>Contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
SepL,RLN-WT,RLN	1.773215	1.162678	3.8	0.0058
SepL,MLN-WT,MLN	2.829324	1.162678	6.9	<.0001
SepL,PsLN-WT,PsLN	1.463793	1.162678	2.528	0.1391
SepL,RLN-SepL,MLN	1.762583	1.284968	2.26	0.2342
SepL,RLN-SepL,PsLN	15.71546	1.284968	10.986	<.0001
SepL,MLN-SepL,PsLN	8.91615	1.284968	8.726	<.0001
WT,RLN-WT,MLN	2.81236	1.284968	4.124	0.0024
WT,RLN-WT,PsLN	12.97315	1.284968	10.222	<.0001
WT,MLN-WT,PsLN	4.612903	1.284968	6.098	<.0001

**Table S7.** IFN $\gamma$  Release Index Tukey comparisons for data in Figure 4B. Pairwise comparisons were made between the  $\Delta sepL$  and WT T3SP preparations across all lymph nodes combined and for both T3SP preparations combined between each lymph node (RLN/MLN/PsLN).

<b>Contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>z</b>	<b>p.value</b>
sepL-WT	2.43204	1.2198	4.473	<0.0001
RLN-MLN	1.68822	1.58056	1.144	0.61659
RLN-PsLN	7.22104	1.58056	4.319	<0.0001
MLN-PsLN	4.2773	1.58056	3.175	0.00578

**Table S8.** Thymidine incorporation Tukey comparisons for data in Figure 4C. Pairwise comparisons were made between each experimental group (Control/PT2128/PT32) for both T3SP preparations combined within each lymph node (RLN/MLN/PsLN).

<b>Node = RLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.751470835	1.56838435	-0.635	0.8024
Control-PT32	1.985953658	1.56838435	1.525	0.2964
PT2128-PT32	2.642755407	1.44406353	2.645	0.0355
<b>Node = MLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	1.38363787	1.56838435	0.722	0.7531
Control-PT32	1.252827276	1.56838435	0.501	0.8715
PT2128-PT32	0.905458938	1.44406353	-0.27	0.9606
<b>Node = PsLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.491327429	1.56838435	-1.579	0.2725
Control-PT32	1.673746493	1.56838435	1.144	0.4962
PT2128-PT32	3.406580609	1.44406353	3.336	0.0071



**Table S9.** IFN $\gamma$  release Tukey comparisons for data in Figure 4D. Pairwise comparisons were made between each experimental group (Control/PT2128/PT32) within each combination of lymph node (RLN/MLN/PsLN) and *ex vivo* stimulant (ConA/Media/WT/WT LPS/sepL/sepL LPS).

<b><i>Ex vivo</i> stimulant = ConA, Node = RLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	1.155679661	2.377298	0.167	0.9847
Control-PT32	2.3756318	2.377298	0.999	0.5811
PT2128-PT32	2.055614441	2.056001	1	0.5814
<b><i>Ex vivo</i> stimulant = Media, Node = RLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.243083723	2.377298	-1.633	0.2421
Control-PT32	0.739760128	2.377298	-0.348	0.9355
PT2128-PT32	3.043231916	2.056001	1.544	0.2818
<b><i>Ex vivo</i> stimulant = WT, Node = RLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.262015926	2.377298	-1.547	0.279
Control-PT32	3.204437312	2.377298	1.345	0.3781
PT2128-PT32	12.22993362	2.056001	3.474	0.0035
<b><i>Ex vivo</i> stimulant = WT LPS, Node = RLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.47105741	2.377298	-0.869	0.6622
Control-PT32	2.132288281	2.377298	0.874	0.659
PT2128-PT32	4.526599593	2.056001	2.095	0.1039
<b><i>Ex vivo</i> stimulant = sepL, Node = RLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.53463088	2.377298	-0.723	0.7511
Control-PT32	3.044201951	2.377298	1.286	0.4104
PT2128-PT32	5.694025661	2.056001	2.413	0.0525
<b><i>Ex vivo</i> stimulant = sepL LPS, Node = RLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.361006457	2.377298	-1.177	0.473
Control-PT32	1.360236424	2.377298	0.355	0.9329
PT2128-PT32	3.767900537	2.056001	1.84	0.1698

<b>Ex vivo stimulant = ConA, Node = MLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	2.889143678	2.377298	1.225	0.4446
Control-PT32	0.939340094	2.377298	-0.072	0.9971
PT2128-PT32	0.325127512	2.056001	-1.559	0.2753
<b>Ex vivo stimulant = Media, Node = MLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.60769764	2.377298	-0.575	0.834
Control-PT32	0.29250592	2.377298	-1.42	0.3394
PT2128-PT32	0.481334621	2.056001	-1.014	0.5722
<b>Ex vivo stimulant = WT, Node = MLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.655027239	2.377298	-0.489	0.8771
Control-PT32	1.267055125	2.377298	0.273	0.9597
PT2128-PT32	1.934354865	2.056001	0.915	0.6339
<b>Ex vivo stimulant = WT LPS, Node = MLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	1.177620914	2.377298	0.189	0.9805
Control-PT32	0.843120502	2.377298	-0.197	0.9788
PT2128-PT32	0.715952385	2.056001	-0.464	0.8886
<b>Ex vivo stimulant = sepL, Node = MLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	1.336551569	2.377298	0.335	0.9401
Control-PT32	1.203697033	2.377298	0.214	0.9751
PT2128-PT32	0.90059902	2.056001	-0.145	0.9884
<b>Ex vivo stimulant = sepL LPS, Node = MLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.902498835	2.377298	-0.118	0.9923
Control-PT32	0.537846244	2.377298	-0.716	0.7552
PT2128-PT32	0.595952272	2.056001	-0.718	0.7543
<b>Ex vivo stimulant = ConA, Node = PSLN:</b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.907359102	2.377298	-0.112	0.9931
Control-PT32	4.37622608	2.377298	1.705	0.2143
PT2128-PT32	4.823036515	2.056001	2.183	0.0866

<b><i>Ex vivo stimulant = Media, Node = PSLN:</i></b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.190852393	2.377298	-1.913	0.1466
Control-PT32	1.362735438	2.377298	0.357	0.9321
PT2128-PT32	7.140258419	2.056001	2.727	0.0251
<b><i>Ex vivo stimulant = WT, Node = PSLN:</i></b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.205716639	2.377298	-1.826	0.1725
Control-PT32	5.902994791	2.377298	2.05	0.1117
PT2128-PT32	28.69478533	2.056001	4.657	0.0001
<b><i>Ex vivo stimulant = WT LPS, Node = PSLN:</i></b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.369841447	2.377298	-1.149	0.4896
Control-PT32	3.927955328	2.377298	1.58	0.2645
PT2128-PT32	10.62064689	2.056001	3.278	0.0061
<b><i>Ex vivo stimulant = sepL, Node = PSLN:</i></b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.419754905	2.377298	-1.002	0.5791
Control-PT32	5.607820191	2.377298	1.991	0.1258
PT2128-PT32	13.35974904	2.056001	3.597	0.0025
<b><i>Ex vivo stimulant = sepL LPS, Node = PSLN:</i></b>				
<b>contrast</b>	<b>Estimate (fold change)</b>	<b>SE</b>	<b>t.ratio</b>	<b>p.value</b>
Control-PT2128	0.283437109	2.377298	-1.456	0.3214
Control-PT32	2.50573437	2.377298	1.061	0.543
PT2128-PT32	8.840530361	2.056001	3.024	0.0119

**Table S10.** Ki67<sup>+</sup> versus Ki67<sup>-</sup> rectal lymph node cell generalised linear model analysis of deviance tables.

<b>CD4<sup>+</sup></b>	Df	Deviance	Residual Df	Residual Deviance	F	Pr(>F)
NULL			59	49000		
Group	2	1728	57	47272	13.5664	2.14E-05
Stimulant	3	44127	54	3145	230.9522	2.20E-16
Group:Stimulant	6	215	48	2930	0.5614	0.7587
<b>CD8<sup>+</sup></b>	Df	Deviance	Residual Df	Residual Deviance	F	Pr(>F)
NULL	59	22757.1				
Group	2	828.2	57	21928.9	7.5486	0.001411
Stimulant	3	19247.2	54	2681.7	116.9524	2.20E-16
Group:Stimulant	6	64.1	48	2617.5	0.1948	0.976762
<b>γδTCR<sup>+</sup></b>	Df	Deviance	Residual Df	Residual Deviance	F	Pr(>F)
NULL	58	2197.29				
Group	2	172.15	56	2025.14	6.3101	0.003737
Stimulant	3	1315.93	53	709.21	32.1573	1.88E-11
Group:Stimulant	6	64.99	47	644.22	0.7941	0.57926
<b>NKp46<sup>+</sup></b>	Df	Deviance	Residual Df	Residual Deviance	F	Pr(>F)
NULL	59	468.48				
Group	2	59.699	57	408.78	7.3698	0.001617
Stimulant	3	188.32	54	220.46	15.4986	3.50E-07
Group:Stimulant	6	51.205	48	169.26	2.1071	0.069641

**Table S11.** Ki67<sup>+</sup> versus Ki67<sup>-</sup> rectal lymph node cell Tukey comparison tables (logit scale)

for data in Figure 5. Pairwise comparisons were made between each *ex vivo* stimulant

(ConA/Media/WT/LPS) within each experimental group.

<b>CD4</b>				
Group = Control				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	4.078103	0.659439	6.184198	<.0001
ConA-WT	2.409936	0.455698	5.288448	<.0001
ConA-LPS	3.539619	0.711232	4.976746	<.0001
Media-WT	-1.66817	0.758423	-2.19952	0.1234
Media-LPS	-0.53848	0.934556	-0.57619	0.9392
WT-LPS	1.129683	0.803863	1.405318	0.496
Group = PT2128				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	3.791895	0.344895	10.99435	<.0001
ConA-WT	1.901821	0.189423	10.04009	<.0001
ConA-LPS	3.528389	0.362439	9.735134	<.0001
Media-WT	-1.89007	0.361278	-5.23163	<.0001
Media-LPS	-0.26351	0.475397	-0.55429	0.9454
WT-LPS	1.626568	0.378062	4.30238	0.0001
Group = PT32				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	3.567561	0.455581	7.830791	<.0001
ConA-WT	2.406768	0.292653	8.223953	<.0001
ConA-LPS	3.432117	0.460661	7.450416	<.0001
Media-WT	-1.16079	0.509831	-2.27682	0.1035
Media-LPS	-0.13544	0.621683	-0.21787	0.9964
WT-LPS	1.025349	0.514375	1.993387	0.1905
<b>CD8</b>				
Group = Control				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	3.540999	0.826799	4.28278	0.0001
ConA-WT	2.698219	0.547318	4.929893	<.0001
ConA-LPS	3.483781	0.775991	4.489461	<.0001
Media-WT	-0.84278	0.836516	-1.00749	0.745
Media-LPS	-0.05722	1.001181	-0.05715	0.9999
WT-LPS	0.785562	0.786336	0.999016	0.75

Group = PT2128				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	3.239418	0.332213	9.751028	<.0001
ConA-WT	2.198237	0.260266	8.446124	<.0001
ConA-LPS	3.396709	0.348758	9.73945	<.0001
Media-WT	-1.04118	0.290367	-3.58575	0.0019
Media-LPS	0.157291	0.371761	0.423097	0.9745
WT-LPS	1.198472	0.309159	3.876555	0.0006
Group = PT32				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	3.010154	0.520678	5.781225	<.0001
ConA-WT	2.095138	0.317463	6.599625	<.0001
ConA-LPS	3.441522	0.51134	6.730398	<.0001
Media-WT	-0.91502	0.518703	-1.76405	0.2909
Media-LPS	0.431368	0.655544	0.65803	0.9127
WT-LPS	1.346383	0.509329	2.643446	0.041
$\gamma\delta\text{TCR}^+$				
Group = Control				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	0.050874	0.654942	0.077677	0.9998
ConA-WT	-0.91047	0.550979	-1.65245	0.3493
ConA-LPS	-0.52537	0.645408	-0.81401	0.8479
Media-WT	-0.96134	0.524664	-1.8323	0.2581
Media-LPS	-0.57624	0.623094	-0.92481	0.7916
WT-LPS	0.385097	0.512713	0.751096	0.8762
Group = PT2128				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	-0.40109	0.218584	-1.83496	0.2569
ConA-WT	-1.10958	0.184644	-6.00928	<.0001
ConA-LPS	-0.16425	0.238394	-0.68898	0.9013
Media-WT	-0.70848	0.205295	-3.45105	0.0031
Media-LPS	0.236844	0.254725	0.929805	0.7889
WT-LPS	0.945328	0.226272	4.177834	0.0002

Group = PT32				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	0.08338	0.304656	0.273686	0.9928
ConA-WT	-1.24554	0.204482	-6.09117	<.0001
ConA-LPS	-0.08588	0.294945	-0.29116	0.9914
Media-WT	-1.32892	0.291707	-4.55566	<.0001
Media-LPS	-0.16926	0.360933	-0.46894	0.9659
WT-LPS	1.159659	0.281549	4.118856	0.0002
<b>NKp46<sup>+</sup></b>				
Group = Control				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	0.663033	0.45719	1.450237	0.468
ConA-WT	-0.78495	0.541547	-1.44947	0.4684
ConA-LPS	0.271985	0.496263	0.548066	0.9471
Media-WT	-1.44799	0.48703	-2.9731	0.0156
Media-LPS	-0.39105	0.436121	-0.89665	0.8066
WT-LPS	1.05694	0.523883	2.017513	0.1815
Group = PT2128				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	-0.06269	0.355501	-0.17636	0.9981
ConA-WT	-0.80107	0.354101	-2.26226	0.107
ConA-LPS	-0.4181	0.393787	-1.06175	0.7129
Media-WT	-0.73837	0.341278	-2.16355	0.1336
Media-LPS	-0.35541	0.382298	-0.92967	0.7889
WT-LPS	0.382964	0.380997	1.005164	0.7464
Group = PT32				
contrast	estimate	SE	z.ratio	p.value
ConA-Media	0.835225	0.384027	2.174914	0.1303
ConA-WT	-1.2282	0.442151	-2.77778	0.0281
ConA-LPS	0.785173	0.379409	2.069464	0.1632
Media-WT	-2.06342	0.401976	-5.1332	<.0001
Media-LPS	-0.05005	0.33172	-0.15089	0.9988
WT-LPS	2.013372	0.397567	5.064234	<.0001

## References

1. **Park KT, Allen AJ, Bannantine JP, Seo KS, Hamilton MJ, Abdellrazeq GS, Rihan HM, Grimm A, Davis WC.** 2011. Evaluation of two mutants of *Mycobacterium avium* subsp. *paratuberculosis* as candidates for a live attenuated vaccine for Johne's disease. *Vaccine* **29**:4709-4719.
2. **Coussens PM, Verman N, Coussens MA, Elftman MD, McNulty AM.** 2004. Cytokine gene expression in peripheral blood mononuclear cells and tissues of cattle infected with *Mycobacterium avium* subsp. *paratuberculosis*: evidence for an inherent proinflammatory gene expression pattern. *Infect Immun* **72**:1409-1422.